EP0462184A1 - Procede de traitement d'infections virales a l'aide de lfa-1 - Google Patents

Procede de traitement d'infections virales a l'aide de lfa-1

Info

Publication number
EP0462184A1
EP0462184A1 EP19900904579 EP90904579A EP0462184A1 EP 0462184 A1 EP0462184 A1 EP 0462184A1 EP 19900904579 EP19900904579 EP 19900904579 EP 90904579 A EP90904579 A EP 90904579A EP 0462184 A1 EP0462184 A1 EP 0462184A1
Authority
EP
European Patent Office
Prior art keywords
subunit
lfa
sequence
human
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19900904579
Other languages
German (de)
English (en)
Other versions
EP0462184A4 (en
Inventor
Timothy A. Springer
Takashi K. Kishimoto
Thomas Roberts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of EP0462184A1 publication Critical patent/EP0462184A1/fr
Publication of EP0462184A4 publication Critical patent/EP0462184A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1777—Integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Definitions

  • This invention relates to cellular adhesion.
  • Cellular adhesion is a critical function for guiding migration and localization of cells, and for maintaining the integrity of the body.
  • Receptors for extracellular matrix components such as fibronectin, laminin, and vitronectin mediate cellular adhesion during morphogenesis and wound healing.
  • regulatory networks require intimate cell-cell interaction among lymphocytes and antigen- presenting accessory cells, and cell-mediated cytolysis involves direct contact between the effector cell and virally-infected or transformed target cells.
  • Leukocyte- endothelial interactions are important in leukocyte mobilization into inflammatory sites and in lymphocyte recirculation.
  • the invention features a) substantially pure recombinant 0-subunit of a human glycoprotein concerned with cellular adhesion, or b) a biologically active fraction of this u-subunit, c) an analog of the /J-subunit, or c) a fragment of the J-subunit, composed of at least 10% of a contiguous sequence of the J-subunit.
  • the invention also features a cDNA sequence encoding for the J-subunit; and a vector containing a DNA sequence encoding therefor.
  • recombinant subunit is meant the polypeptide product of recombinant DNA encoding the /3-subunit, i.e., the polypeptide expressed from DNA which is not in its naturally occurring location within a chromosome.
  • natural subunit is meant that subunit produced naturally in vivo from naturally occurring and located DNA.
  • analog is meant a polypeptide differing from the normal polypeptide by one or more amino acids, but having substantially the biological activity of the normal polypeptide.
  • the invention also features any monoclonal antibody (MAb) raised against the recombinant B- subunit, a biologically active fraction, an analog, or a fragment thereof composed of at least 10%, preferably at least 80%, of a contiguous sequence of the ⁇ -subunit of a human glycoprotein.
  • MAb monoclonal antibody
  • the cDNA sequence encoding the LFA-1 /5-subunit or a fragment thereof may be derived from any of the naturally occurring genes encoding it, or synthesized chemically. Variations in this sequence which do not alter the amino acid sequence of the resulting protein, or which do not significantly alter the biological activity of the protein, are also acceptable, and are within this invention.
  • the human glycoprotein is LFA-1, Mac-I or pl50.95.
  • the invention permits the diagnosis and treatment of a variety of human disease states.
  • Fig. I is the DNA coding sequence of the alpha-subunit of LFA-1, Mac-I and pl50.95. Potential N-glycosylation sites are marked with triangles.
  • Figure 2 is a comparison of the amino acid sequence predicted from the cDNA in Fig. 1, and the amino acid sequence derived from enzyme digests of the alpha-subunit of LFA-1. Ambiguous determinations of amino acids are bracketed.
  • the code for amino acids is as follows:
  • Trp Trp, w -tryptophan
  • the 0-subunit of any of the above described related glycoproteins is isolated by standard procedures and the amino acid sequence of at least a part of it determined. From this analysis a synthetic oligonucleotide probe, corresponding to the amino acid sequence, is synthesized and used as a probe for a genomic or cDNA library containing a DNA sequence encoding the /J-subunit. An example of this procedure is given below. One skilled in the art will realize that this represents only one of many methods which can be used to achieve cloning of the gene encoding the LFA-1 0-subunit.
  • the pl50.95 protein was purified from hairy cell leukemia spleens (Miller et al., 1986, 137 J. Immunol. 2891, hereby incorporated by reference); Mac-1 was purified from pooled human leukocytes (Miller et al., supra); and LFA-1 was purified from the SKW3 T cell line using TS1/22 monoclonal antibody (Sanchez-Madrid et al . 1983, J. Exp. Med. 158:586, hereby incorporated by reference).
  • SUBSTITUTESHEET the level of free radicals in the gel. Bands were visualized by soaking the gel for several minutes in 1 M KCI and then excised. The 0-subunit was electroeluted using the apparatus and method described by Hunkapillar et al., supra. The purified protein was reduced with 2 mM DTT in the presence of 2% SDS and alykylated with 5 mM iodoacetic acid in the dark. (In some cases, the protein was reduced and alkylated prior to running the preparative gel.)
  • the tryptic peptides were resolved by reverse phase HPLC (Beckman Instruments) with a 0.4 X 15 cm C4 column (Vydac, Hesperig, CA), and eluted from a 2 hr linear gradient from 0 to 60% acetonitrile. 0.1% TFA was included in both the aqueous and organic solvents. The peaks were monitored at 214 and 280 nm and collected into 1.5 ml polypropylene tubes. The fractions were concentrated to 30 ⁇ or less on a speed-vac apparatus, and selected peptides subjected to sequence analysis using a gas phase icrosequenator (Applied Biosyste s, Foster City, CA).
  • fl-subunit of pl50.95 pl50,95 was affinity purified from the spleens of human patients with hairy cell leukemia using a monoclonal antibody specific for the alpha subunit (MW approx. 150,000, Miller et al., su p ra ) .
  • Analysis of the purified protein by SDS-PAGE and silver staining revealed the characteristic alpha and beta
  • SUBSTITUTESHEET subunit with no significant amounts of contaminating proteins.
  • the /J-subunit band was excised from a preparative SDS-PAGE gel and electroeluted, as described above.
  • the N-terminus of the beta subunit was blocked and therefore could not be sequenced.
  • Internal amino acid sequence information was obtained by digesting the /J-subunit with trypsin. The tryptic peptides were resolved by reverse phase HPLC and eluted on a 60% acetonitrile gradient. Peaks analyzed by absorbance at 214 and 280 nm were collected and applied to a gas phase microsequenator.
  • the peptide sequences of two of these fragments is: P-61 Peptide Sequence: LeuTyrGluAsnAsnlleGlnProIlePheAlaValThrSer P-20 Peptide Sequence: ThrAspThrGlyTyrlleGlyLys.
  • oligonucleotide probes Two strategies were adopted for constructing oligonucleotide probes.
  • a unique sequence 39mer was designed from peptide P-61 based on human codon usage frequency (Lathe, 1985. J. Mol. Biol. 183:1). Its sequence is: 3'- GACATACTCTTGTTGTAGGTCGGGTAGAAACGACACTGG -5'.
  • two sets of mixed sequence probes were constructed such that every possible sequence was represented.
  • a 20mer of 96-fold redundancy was derived from peptide P-61, and a 17mer of 192- fold redundancy was constructed based on the sequence from a different peptide fragment of the J-subunit, P-20.
  • the 39mer and the mixed sequence 20mer were used to probe a Northern blot of poly A+selected RNA from PMA-activated U937 cell s.
  • SUBSTITUTE SHEET and C03 cells (Springer et al., 1984, J. Exp. Med. 160:1901, an EBV-transformed cell line from a healthy donor) were grown in RPMI 1640 containing 10-15% fetal calf serum in a - humidified atmosphere of 5% C0 2 and 37 ⁇ C.
  • the U937 cells were activated with 2 ng/ l PMA for three days prior to harvesting.
  • the cells were lysed in a 4M guanidinium isothiocyanate solution, and RNA isolated in a 5.7M CsCl gradient.
  • RNA was selected with oligo (dT)- cellulose columns (Maniatis et al., Molecular Cloning: A laboratory manual, Cold Spring Harbor Laboratory, N.Y., 1982) or oligo (dT)-affinity paper (Amersham). This RNA was denatured and sized on a 1% agarose gel containing formaldehyde (Maniatis et al , supra) and transferred to nylon membranes (BioRad) in 20X SSC. A lane containing 28S and 18S ribosomal RNA from human cells or 23S and 16S rDNA from Escherichia coli was run to provide molecular weight standards.
  • the filters were hybridized with nick-translated probe DNA at 42°C for 18 hr in 5 x SSPE, 50%- formamide, 10% dextran sulfate, 1 X Denhardts, 0.5% SDS and 100 ug/ml denatured salmon sperm DNA, and washed at high stringency (65 ⁇ C) in 0.2X SSC and 0.1% SDS. Both probes identified a band of approximately 3 kb. The 39mer gave a much stronger signal and was chosen for the primary screening of a cDNA library.
  • a human tonsil cDNA library (gift of L. Vogelstein) was size-selected for inserts of 2kb or greater and constructed in ⁇ gtll (Wong et al., 1985, Proc. Nat. Acad. Sci . U.S.A. 82:7711).
  • the original library of 4 X 10 5 reco binants was amplified once, and 200,000 recombinants plated at a density of 7500 plaques/100mm plate.
  • the plaques were amplified in situ on duplicate nitrocellulose filters, as described by Woo (1979, Meth. Enzym. 68:389).
  • the oligonucleotide probes were labeled with 32p_Ajp using polynucleotide kinase.
  • the filters were prehybridized for at least 2 hr at 42 ⁇ C in 6 X SCC, 1 X Denhardts, 0.5% SDS, 0.05% phosphate buffer, and 100 ⁇ g/ml of salmon sperm DNA.
  • Hybridization with the 39mer was overnight at 42 ⁇ C in prehybridization solution containing 20 ⁇ g/ml tRNA.
  • the filters were washed at 53°C to 55 ⁇ C with 6 X SSC, 0.1% SDS, and 0.05% phosphate buffer.
  • the damp filters were covered with plastic wrap and exposed to film with an intensifying screen. Phage that gave positive signals on duplicate filters were plaque purified and rescreened with the 39mer at a higher wash temperature (60 ⁇ C) and with 20mer and 17mer mixed sequence probes. 15 positive clones were picked. Eight of the clones crossreacted with each other and gave positive signals with the 20mer mixed sequence probe and the independent 17mer mixed sequence probe. These clones were chosen for further analysis.
  • a 263 bp Pstl/EcoRI restriction fragment which hybridized to the 39mer was subcloned into Ml3 vector and sequenced by the Sanger dideoxy chain termination method as follows.
  • the amino acid sequence deduced from the DNA sequence is identical in 13 of 14 positions to the peptide sequence from which the 39mer probe was derived, including one amino acid which was not included in the design of the oligonucleotide.
  • the predicted amino acid sequence shows that this peptide is preceded by a lysine and followed by an arginine, as expected for a tryptic fragment.
  • the one mismatch may be due to normal polymorphism.
  • the unique sequence oligonucleotide was 87% homologous to the cDNA sequence, despite the one amino acid mismatch.
  • the cDNA clones were restriction ' mapped by single and double restriction digests and, after end-labeling, by partial restriction digests (Maniatis et al., supra). Compatible
  • SUBSTITUTESHEET restriction fragments were subcloned directly into Ml3 cloning vectors. Other fragments were first blunt ended with Klenow, T4 polymerase, or Mung Bean nuclease (Maniatis et al., supra) and ligated into the Hindi or Smal site of the M13 polylinker. The nucleotide sequence of both strands was determined by the dideoxy chain termination method of Sanger et al. (1977, Proc. Nat. Acad. Sci. U.S.A. 74:5463) using 35 S- dATP.
  • the first ATG is at position 73, and the sequence surrounding the ATG is consistent with the consensus rules for an initiation codon (Kozak 1984, Nucl . Acid. Res. 12:857).
  • This putative initiation codon is followed by an open reading frame of 2304 bp, which could encode a polypeptide of 769 amino acids (aa).
  • the stop codon ATC is followed by a 3' untranslated region of 394 bp.
  • the poly A tail was not found, although a consensus polyadenylation signal (AATAAA) is located 9 bp from the 3' end.
  • AATAAA consensus polyadenylation signal
  • the deduced amino acid sequence of the cDNA clones was compared to peptide sequence data from the beta subunit of Mac-1, LFA-1, and pl50,95 (Fig. 2).
  • one other peptide was sequenced from the beta subunit of pl50,95. Tryptic peptides were also prepared and analyzed from the beta subunit of purified Mac-1 and LFA-1. Each peptide sequence is found within the deduced amino acid sequence (Figs. 1 and 2). Thus, it can be concluded that the cDNA encodes the /J-subunit of human LFA-1.
  • the cDNA clones hybridize to a single RNA species of approximately 3.0 kb, which is the same message identified by the 39mer oligonucleotide. This message is present in PMA- activated U937 cells (LFA-1+, Mac-1+, pl50,95 + ), JY
  • SU BSTITUTESHEET lymphoblastoid cells LFA-1+, Mac-T, pl50,95 “
  • EBV- transformed cells from a normal donor (LFA-1 + , Mac-1 " , pl50,95 “ ), but is absent in HeLa cells (LFA-1 " Mac-1 " , p!50, 95”).
  • clone 18.1.1 lacks the poly A tail, it is close to the estimated size of the RNA message.
  • the first domain which begins with the putative initiation methionine and extends 22 amino acids, has the characteristics of a signal sequence. This putative signal sequence is followed by a charged glutamine, a residue which is often cyclized at the N-terminal position. This would be consistent with the N-terminal blockage of the ⁇ - subunit, if the signal sequence is cleaved during processing.
  • the cDNA encoding the /J-subunit of human LFA-1 can be used to produce recombinant /J-subunit in large amounts.
  • the beta-subunit-encoding cDNA can be excised from the ⁇ gtll clones and introduced into an expression vector (plas id, cosmid, phage or other type) to express the ⁇ - subunit in J coli. using standard techniques.
  • the clones may be inserted into other vectors, such as mammalian, insect, or yeast expression vectors, and used to produce recombinant /3-subunit in mammalian or yeast cells.
  • the subunits produced by the above methods can be readily purified and used as an immunogen to raise monoclonal antibodies to the subunits.
  • These antibodies can be labelled and used in standard immunoassays to monitor the level of LFA- 1, Mac-1, or pl50,95 in white blood cells, and in the serum or other body fluids of patients having medical disorders associated with too many or too few cells having on their surfaces LFA-1 or related proteins.
  • diseases e.g., AIDS, characterized by im unosuppression can be expected
  • S U BSTITUTESHEET to be accompanied' by abnormally low levels of such cells, which are instrumental in fighting infections, and such diseases can thus be monitored by monitoring levels of these proteins.
  • other disease states e.g., autoimmune disease, allograft rejection, and graft-versus-host disease
  • autoimmune disease can be expected to be characterized by abnormally high levels of such cells, and thus also can be monitored by monitoring levels of these proteins.
  • They can also be used to diagnose leukocyte adhesion deficiency, an inherited deficiency in the LFA-1, Mac-1, and pl50,95 glycoproteins.
  • Antibodies to the B- subunit can also be used to purify LFA-1 or related proteins by conventional im unoaffinity purification methods.
  • the purified proteins can also be used therapeutically.
  • the proteins can be administered to patients in need of such treatment in an effective amount (e.g., from 20-500 ⁇ g per kg body weight), and mixed with a pharmaceutically acceptable carrier substance such as saline.
  • Therapeutic utility of these proteins is based on the fact that disease states such as autoimmune diseases, allograft rejections, and graft-versus-host diseases involve abnormally high levels of cell-to-cell contact mediated by the recognition and binding of LFA-1 and related proteins to target antigen presenting cells, endothelial cells, and other types of cells.
  • LFA-1 or a related protein, or fragments thereof will compete for receptors for the cell-bound protein, inhibiting cell-to-cell binding and thus bringing about the desired immunosuppression.
  • a particular disease for which these proteins will be useful is the autoimmune disease rheumatoid arthritis.
  • administration is intravenous at about 20-500 ⁇ g per kg body weight, or directly at an inflamed joint of a patient suffering from rheumatoid arthritis.
  • oral administration or local application can be used by providing
  • the amount and method of administration will vary dependent upon the age and weight of the patient, and the disease to be treated.
  • Other autoimmune diseases which can be treated include systemic lupus erythematosis, juvenile onset diabetes, multiple sclerosis, allergic conditions, eczema, ulcerative colitis, inflammatory bowel disease, Crohn's disease, as well as allograft rejections (e.g., rejection of a transplanted kidney or heart).
  • LFA-1, Mac-1, and p!50,95 normally act in situ by binding to endothelial and other cells.
  • the free proteins or peptides, which are administered will be able to inhibit leukocyte immune responses and migration to inflammatory sites.
  • the ⁇ subunit cDNA clone can be used in prenatal diagnosis of leukocyte adhesion deficiency (LAD).
  • LAD disease is a deficiency in cell surface expression of LFA-1, Mac-1, and pl50,95 and is due at least in part to a primary genetic lesion in the ⁇ subunit.
  • Patients with the severe form of LAD disease suffer from recurrent bacterial infections and rarely survive beyond childhood.
  • the defect can be detected early in pregnancy since it is associated with a unique restriction fragment length polymorphism.
  • PstI digestion of human DNA and hybridization with the 1.8 kb EcoRI fragment (shown in Fig. 2) of the ⁇ subunit cDNA defines a restriction fragment length polymorphism (RFLP).
  • Diagnosis of this disease is therefore performed by standard procedure using the whole or a part of this EcoRI fragment.
  • the genomic DNAs of the parents of the fetus, and the fetus are screened with this probe and an analysis of their RFLPs made. In this way the probability that the fetus has the disease can be estimated.
  • ICAMs such as ICAM-1
  • ICAM-1 are recognized by certain human viruses (particularly rhinoviruses of the major type (which bind to ICAM-1). These viruses bind to human cells by virtue of this recognition, and thereby mediate viral infection.
  • SUBSTITUTESHEET Thus, a central step in the etiology of viral disease is the interaction between these cellular receptors and the virus.
  • Agents which suppress, compete with, or inhibit the ability of a virus to bind to an ICAM molecule thus have use in the treatment of viral (and particularly rhinoviral) infection.
  • One aspect of the present invention thus concerns the ability of the beta-subunit of human LFA-1, and its functional derivatives to interact with ICAM-1 and to thereby either prevent cell-viral attachment and viral infection, or to attenuate or diminish the severity or duration of such infection.
  • Such agents are preferably provided to a recipient patient as a heterodimer containing the molecule in association with a molecule of the ⁇ -subunit of a member of the CD-18 family (such as the ⁇ - subunits of LFA-1, pl50,95, or Mac-1).
  • the above-described goal of treating viral infection may be accomplished with a single agent or with a combination of more than one agents.
  • the above- described agent(s) of the present invention is to be provided to a recipient patient (for example, by intranasal means) at a dosage sufficient to permit the agent(s) to suppress, compete with, or inhibit the ability of a virus to bind to an ICAM molecule.
  • a dosage shall, in general, be (for each agent provided) from 0.01 pg/kg patient weight to 1 mg/kg patient weight, although greater or lesser amounts can be employed.
  • the administration of such agent(s) may be provided either “prophylactically” or “therapeutically.”
  • administration of such agent(s) may be provided either “prophylactically” or “therapeutically.”
  • the agent(s) are provided in advance of (i.e. prior to, at, or shortly after) the time of infection but in advance of any symptoms of viral infection.
  • the prophylactic administration of the agent(s) serves to prevent or attenuate any subsequent infection.
  • the agent(s) are provided at (or shortly after) the onset of a symptom of actual viral infection (such as, for example, the appearance of virally induced nasal congestion, etc. or the detection of virus in bodily fluids, or the detection of antibodies, directed against the virus, in the serum of an infected patient, etc).
  • the therapeutic administration of the agent(s) serves to attenuate any actual infection, and thus lessen its severity or duration.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne une sous-unité beta de recombinaison sensiblement pure d'une glycoprotéine humaine relative à l'adhérence cellulaire, ou une fraction biologiquement active, un analogue ou un fragment de celle-ci, composé d'au moins 10 % d'une séquence contiguë de la sous-unité beta, une séquence d'ADNc codante à cet effet, ainsi qu'un vecteur contenant une séquence d'ADN codante à cet effet. L'invention concerne également tout anticorps monoclonal développé contre la sous-unité beta de LFA-1 humaine, ainsi qu'un procédé de traitement d'infections rhinovirales à l'aide de LFA-1.
EP19900904579 1989-03-09 1990-03-09 Method of treating viral infections using lfa-1 Withdrawn EP0462184A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32123789A 1989-03-09 1989-03-09
US321237 1999-05-27

Publications (2)

Publication Number Publication Date
EP0462184A1 true EP0462184A1 (fr) 1991-12-27
EP0462184A4 EP0462184A4 (en) 1992-01-08

Family

ID=23249765

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19900904579 Withdrawn EP0462184A4 (en) 1989-03-09 1990-03-09 Method of treating viral infections using lfa-1

Country Status (4)

Country Link
EP (1) EP0462184A4 (fr)
JP (1) JPH04505009A (fr)
CA (1) CA2050329A1 (fr)
WO (1) WO1990010652A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA896668B (en) * 1988-09-01 1990-06-27 Molecular Therapeutics Inc A human rhinovirus receptor protein that inhibits virus infectivity
US5674982A (en) * 1990-07-20 1997-10-07 Bayer Corporation Multimeric form of human rhinovirus receptor protein
US6107461A (en) * 1990-07-20 2000-08-22 Bayer Corporation Multimeric forms of human rhinovirus receptor and fragments thereof, and method of use
US5686582A (en) * 1990-07-20 1997-11-11 Bayer Corporation Multimeric forms of human rhinovirus receptor protein
JPH06511156A (ja) * 1992-07-16 1994-12-15 イコス　コーポレイション 炎症性疾患状態に関連する症状の緩和
MX9305070A (es) * 1992-08-21 1994-04-29 Genentech Inc Compocicion farmaceutica que contiene un antagonista de lfa-1 para el tratamiento de transtornos o desordenes mediados por el lfa-1
US5914112A (en) * 1996-01-23 1999-06-22 Genentech, Inc. Anti-CD18 antibodies in stroke
US20020081294A1 (en) 1996-01-23 2002-06-27 Genentech, Inc. Co-administration of a thrombolytic and an anti-CD18 antibody in stroke
US6582698B1 (en) 1999-03-19 2003-06-24 Genentech, Inc. Treatment method
IL145480A0 (en) 1999-03-19 2002-06-30 Genentech Inc Treatment of lfa-1 associated disorders with increasing doses of lfa-1
AU4192000A (en) * 1999-04-02 2000-10-23 Abbott Laboratories Lfa-1 regulatory binding site and uses thereof
AU2001230920A1 (en) * 2000-01-14 2001-07-24 Genentech Inc. Diagnosis and treatment of hepatic inflammatory disorders by inhibiting the binding of lfa-1 to icam-1
PT1682537E (pt) 2003-11-05 2012-06-20 Sarcode Bioscience Inc Moduladores de adesão celular
RU2006146939A (ru) 2004-06-09 2008-07-20 Дженентек Способ лечения кольцевидной гранулемы или саркоида
ES2614080T3 (es) 2005-05-17 2017-05-29 Sarcode Bioscience Inc. Composiciones y métodos para el tratamiento de trastornos oculares
ES2830024T3 (es) 2007-10-19 2021-06-02 Novartis Ag Composiciones y métodos para el tratamiento del edema macular
US8080562B2 (en) 2008-04-15 2011-12-20 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
WO2011050175A1 (fr) 2009-10-21 2011-04-28 Sarcode Corporation Agent pharmaceutique cristallin et procédés de préparation et utilisation de celui-ci
JP6607780B2 (ja) 2012-07-25 2019-11-20 サルコード・バイオサイエンス・インコーポレイテッド Ｌｆａ−１阻害剤およびその多形

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988006592A1 (fr) * 1987-02-26 1988-09-07 Dana-Farber Cancer Institute, Inc. Clonage de lfa-1
EP0362531A1 (fr) * 1988-09-01 1990-04-11 Bayer Corporation Protéine du récepteur du rhinovirus humain, qui inhibe le caractère infectieux du virus
EP0362526A2 (fr) * 1988-08-23 1990-04-11 Dana Farber Cancer Institute Sous-unité du récepteur d'adhésion de leucocyte LFA-1
EP0364690A2 (fr) * 1988-08-23 1990-04-25 Dana Farber Cancer Institute Sous-unité du récepteur d'adhésion de leukocyte Mac-1
WO1990013316A1 (fr) * 1989-04-28 1990-11-15 Baylor College Of Medicine Dissemination de cellules infectees par l'hiv-1

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988006592A1 (fr) * 1987-02-26 1988-09-07 Dana-Farber Cancer Institute, Inc. Clonage de lfa-1
EP0362526A2 (fr) * 1988-08-23 1990-04-11 Dana Farber Cancer Institute Sous-unité du récepteur d'adhésion de leucocyte LFA-1
EP0364690A2 (fr) * 1988-08-23 1990-04-25 Dana Farber Cancer Institute Sous-unité du récepteur d'adhésion de leukocyte Mac-1
EP0362531A1 (fr) * 1988-09-01 1990-04-11 Bayer Corporation Protéine du récepteur du rhinovirus humain, qui inhibe le caractère infectieux du virus
WO1990013316A1 (fr) * 1989-04-28 1990-11-15 Baylor College Of Medicine Dissemination de cellules infectees par l'hiv-1

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF IMMUNOLOGY, vol. 137, no. 5, 1st September 1986, pages 1688-1694, The American Association of Immunologists, US; S. KOHL et al.: "The genetic deficiency of leukocyte surface glycoprotein Mac-1, LFA-1, p150,95 in humans is associated with defective antibody-dependent cellular cytotoxicity in vitro and defective protection against herpes simplex virus infection in vivo" *
See also references of WO9010652A1 *

Also Published As

Publication number Publication date
CA2050329A1 (fr) 1990-09-10
JPH04505009A (ja) 1992-09-03
WO1990010652A1 (fr) 1990-09-20
EP0462184A4 (en) 1992-01-08

Similar Documents

Publication Publication Date Title
US5739032A (en) Cloning LFA-1
EP0462184A1 (fr) Procede de traitement d'infections virales a l'aide de lfa-1
Medof et al. Cloning and characterization of cDNAs encoding the complete sequence of decay-accelerating factor of human complement.
US5773578A (en) Proteins produced by human lymphocytes, DNA sequence encoding these proteins and their pharmaceutical and biological use
Verhoeven et al. Characterization of two monoclonal antibodies against cytochrome b558 of human neutrophils
Allen et al. Isolation and expression of functional high-affinity Fc receptor complementary DNAs
US6570000B1 (en) DNA encoding the T cell surface protein CD4 and use of fragments of CD4 in the treatment of AIDS
CA1341293C (fr) La sous-unite alpha de recepteur d'adhesion de leukocyte de la mac-1
EP0362526B1 (fr) Sous-unité du récepteur d'adhésion de leucocyte LFA-1
US6380360B1 (en) Polycystic kidney disease 1 gene and uses thereof
KR0169728B1 (ko) 세포간 부착 분자-2
CA2293735A1 (fr) Variants de lag-3 obtenus par epissage
Pepe et al. A heterozygous splice site mutation in COL6A1 leading to an in-frame deletion of the α1 (VI) collagen chain in an Italian family affected by Bethlem myopathy
EP0729300A1 (fr) Nouvelle proteine fas et procedes d'utilisation
Reiser et al. Cloning and expression of a cDNA for the T-cell-activating protein TAP.
US20030175212A1 (en) Use of soluble gammadelta T cell receptors for regulating T cell function
US5169835A (en) Pregancy specific proteins applications
EP0462205A4 (en) Leukocyte adhesion receptors
WO1995004756A1 (fr) Proteines inhibitrices complementaires de primates non humains
NZ244853A (en) Antibodies and fragments to icam-1, pharmaceutical composition

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19910913

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19911121

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: KISHIMOTO, TAKASHI, K.

Inventor name: ROBERTS, THOMAS

Inventor name: SPRINGER, TIMOTHY, A.

17Q First examination report despatched

Effective date: 19931122

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19940604